Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Sponsor: Eikon Therapeutics
Summary
This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.
Official title: A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 89 Years
Study Type
INTERVENTIONAL
Enrollment
156
Start Date
2023-12-11
Completion Date
2027-12-01
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
IMP1734
PARP1 selective inhibitor
Locations (53)
The University of Arizona Cancer Center
Tucson, Arizona, United States
University of Arkansas Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas, United States
Hoag Health Center Irvine
Irvine, California, United States
University California Irvine
Irvine, California, United States
Sharp Memorial Hospital
San Diego, California, United States
University of California San Francisco (UCSF)
San Francisco, California, United States
Sarah Cannon Research Institute Health One
Denver, Colorado, United States
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, United States
Advent Health Research Institute
Celebration, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Henry Ford Health
Detroit, Michigan, United States
University of Minnesota-Clinical Research Unit
Minneapolis, Minnesota, United States
Washington University - Siteman Cancer Center
St Louis, Missouri, United States
John Theurer Cancer Center
Hackensack, New Jersey, United States
Cayuga Medical Center
Ithaca, New York, United States
Lifespan Cancer Institute
Providence, Rhode Island, United States
Medical University of South Carolina (MUSC) - Hollings CC
Charleston, South Carolina, United States
West Cancer Center & Research Institute
Germantown, Tennessee, United States
Sarah Cannon Research Institue Oncology
Nashville, Tennessee, United States
START - South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
START Mountain Region
West Valley City, Utah, United States
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia
Mater Cancer Care Centre, Mater Misericordiae Limited
South Brisbane, Queensland, Australia
Gold Coast Private Hospital
Southport, Queensland, Australia
Macquarie University
Sydney, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peninsula and south eastern haematology and oncology group
Frankston, Victoria, Australia
Cross Cancer Institute
Edmonton, Alberta, Canada
Sunnybrook Research Institute
Toronto, Ontario, Canada
Princess Margaret Cancer Centre-University Health Network
Toronto, Ontario, Canada
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Chongqing University Cancer Hospital
Chongqing, China
Zhejiang Cancer Hospital
Hangzhou, China
Fudan University Shanghai Cancer Center
Shanghai, China
Righospitalet
Copenhagen, Denmark
Hospices Civils de Lyon - CHU Lyon Sud
Pierre-Bénite, Rhone, France
CLCC François Baclesse
Caen, France
Institut Gustave Roussy
Villejuif, France
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea
Gachon University - Gil Medical Center
Incheon, Namdong-gu, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Hospital Universitari Parc Taulí
Sabadell, Barcelona, Spain
Hospital Clinico San Carlos
Madrid, Madrid, Spain
Clínica Universidad de Navarra - Hospital
Pamplona, Navarre, Spain
Hospital del Mar
Barcelona, Spain
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Fundacion MD Anderson Cancer Center
Madrid, Spain
START Madrid Fundación Jiménez Díaz
Madrid, Spain
START-CIOCC HM Sanchinarro Hospital
Madrid, Spain
Universidad De Sevilla - Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Clinico Universitario de Valencia - INCLIVA
Valencia, Spain